Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Tempus Closes $100M Series G Round

Tempus Closes $100M Series G Round

Mar 13, 2020
|
staff reporter

NEW YORK – Tempus said Friday that it has closed a $100 million Series G round of funding, bringing the company's total capital raised since its founding in 2015 to $620 million and its valuation to $5 billion.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

UK Funds Challenge Trial

The UK is investing £33.6 million into a controversial human SARS-CoV-2 challenge study, according to Reuters.

Watching the Changes

The Guardian reports that the UK COVID genomics consortium is monitoring mutations that are arising within circulating SARS-CoV-2 strains for any that may affect future vaccines.

Max Planck, Nature Strike a Deal

Science reports that Max Planck and Nature have struck a deal for affiliated authors to publish papers that are accessible to the public as well as access Nature-branded journals.

PNAS Papers on Ancient Tibetan Animals, HNSCC Drug Response, More

In PNAS this week: genomic analysis of ancient animals from Tibet, oncoproteins tied to WEE1 kinase enzyme inhibitor response, and more.

What's Popular?

In Business News

  1. CMS Colon Cancer Screening Memo Bodes Well for Assays in Development; Denies Epi ProColon

  2. Proteintech Acquires Recombinant Reagent Manufacturer ChromoTek

  3. SVB Leerink Initiates Coverage of Twist Bioscience With Market Perform Rating

  4. NRGene, Agriplex to Offer Mid-Density Genotyping Services

  5. LumiraDx Gets FDA Emergency Use Authorization for PCR-Based Coronavirus Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.